Ye Edward Tian

This inventor holds 16 USPTO granted patents and 13 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Kinase Inhibitors. Top assignees: Impact Therapeutics, Inc., Impact Therapeutics (Shanghai), Inc, Other. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ye Edward Tian. Retrieved from https://idiyas.com/inventor/ye-edward-tian

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 13)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 11)

EPO Patents = 6 (Patent Applications = 17)

Average Co-Inventor Count = 3.8

ph-index = 3

Forward Citations = 16(Granted Patents)

Location History:

Jiangsu, CN (2015 - 2022)
Shanghai, CN (2020 - 2023)

Company Filing History:

8 out of 11

Impact Therapeutics, Inc.

patents

7 out of 9

Impact Therapeutics (Shanghai), Inc

patents

1 out of 834,570

Other

patents

Years Active: 2015-2026

Loading Chart...

Areas of Expertise:

Pyrazoloquinazolinone

Imidazoquinoxaline

Kinase Inhibitors

PARP Inhibitors

Heteroaromatic Compounds

Tricyclic Compounds

Fused Compounds

Cell Proliferation Inhibitors

Hedgehog Pathway

Aryl Compounds

Diones

Pyrimidinones

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12673951 - Substituted pyrazoloquinazolinone compounds and application thereof (2026-07-07),

2. 12653830 - Substituted imidazoquinoxaline compounds and uses thereof (2026-06-16),

3. 12492197 - 3,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof (2025-12-09),

4. 12479848 - Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof (2025-11-25),

5. 11547703 - Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof (2023-01-10),

6. 11358955 - 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof (2022-06-14),

7. 11345711 - 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones (2022-05-31),

8. 11345710 - Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof (2022-05-31),

9. 10874670 - Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof (2020-12-29),

10. 10703759 - 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones (2020-07-07),

11. 10676468 - N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof (2020-06-09),

12. 10316027 - 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof (2019-06-11),

13. 9926304 - 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof (2018-03-27),

14. 9290460 - [object Object] (2016-03-22),

15. 9199983 - 3-aryl-6-aryl-[1,2,4]triazolo[4,3-α]pyridines as inhibitors of cell proliferation and the use thereof (2015-12-01),

Title: Ye Edward Tian: Innovator in Kinase Inhibitors

Introduction

Ye Edward Tian is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of kinase inhibitors. With a total of 16 patents to his name, Tian's work is paving the way for new therapeutic options in cancer treatment.

Latest Patents

Among his latest patents, Tian has developed substituted fused heteroaromatic tricyclic compounds as kinase inhibitors. This innovation relates to compounds that can be used to treat clinical conditions caused by DNA damage response (DDR) functional defects, such as cancer. The compounds are designed to inhibit ATM kinase, which plays a crucial role in cellular responses to DNA damage. Another notable patent involves 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors, which are also represented by a specific formula. These compounds have the potential to offer new avenues for cancer therapy.

Career Highlights

Tian has worked with several companies throughout his career, including Impact Therapeutics, Inc. and Impact Therapeutics (Shanghai), Inc. His experience in these organizations has allowed him to focus on innovative drug development and contribute to advancements in cancer treatment.

Collaborations

Tian has collaborated with notable colleagues in his field, including Sui Xiong Cai and Xiaozhu Wang. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic compounds.

Conclusion

Ye Edward Tian's contributions to the field of kinase inhibitors and his innovative patents are making a significant impact in the fight against cancer. His work exemplifies the importance of research and collaboration in advancing medical science.

Profile summary based on public USPTO records.